Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hepatopancreatobiliary Surgery Institute of Gansu Province
With
Renmin Hospital of Wuhan University
LanZhou University
Minda Hospital Affiliated to Hubei University for Nationalities
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture
Tianjin Second People's Hospital
Shenyang Sixth People's Hospital
Guangxi Zhuang Autonomous Region
Shenzhen Third People's Hospital
Ankang Central Hospital
Xingtai People's Hospital
Dalian Sixth People's Hospital
The Central Hospital of Lishui City
Affiliated Hospital of Jiangsu University
Suizhou Hospital, Hubei University of Medicine
Coronavirus disease 2019 (COVID-19) pandemic with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become a global challenge. Though most cases of COVID-19 are mild, the disease can also be fatal. Patients with liver cirrhosis are more susceptible to damage from SARS-CoV-2 infection considering their immunocompromised status. The spectrum of disease and factors that influence the disease course in COVID-19 cases with liver cirrhosis are incompletely defined. This muilticentre observational study (COVID-Cirrhosis-CHESS2002) aims to study the clinical characteristics and risk factors associated with specific outcomes in COVID-19 patients with pre-existing liver cirrhosis.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1\) Aged 18 or above;
2\) Laboratory-confirmed COVID-19 infection;
3\) Pre-existing liver cirrhosis based on liver biopsy or clinical findings.
